P27726.P08.doc

ec'd P27PTO 1 2 SEP 2009 EENBLUM & BERNSTE **Intellectual Property Causes**

1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191

Attorney Docket No. P27726

In re applications

SEP 12 2005

Mail Stop Amendment

Application No.

: 10/532.580

(U.S. National Stage of PCT/KR2003/002339) Group Art Unit: Not Yet Assigned

Filed

Névember 4, 2003

Examiner: Not Yet Assigned

For

PORCINE UROPLAKIN II PROMOTER AND THE PRODUCTION METHOD OF-USEFUL PROTEINS USING SAID PROMOTER

Mail Stop Amendment

Commissioner for Patents

U.S. Patent and Trademark Office

Customer Service Window, Mail Stop Amendment

Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

Transmitted herewith is a Supplemental Preliminary Amendment in the above-captioned application.

X Small Entity Status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a previously filed statement.

A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.

X An Information Disclosure Statement, PTO Form 1449, and references cited.

No additional fee is required.

The fee has been calculated as shown below:

Claims After Amendment	No. Claims Previously Paid For	Present Extra	Small Entity		Other Than A Small Entity	
			Rate	Fee	Rate	Fee
Total Claims: 49	*20	29	X25=	. \$	x 50=	\$725.00
Indep. Claims: 1	**3	0	X100=	\$	X200=	\$0.00
Multiple Dependent Claims Presented			+180=	\$	+360=	\$0.00
Extension Fees for Month(s)				\$		\$0.00
			Total:	\$	Total:	\$725.00

Please charge my Deposit Account No. 19-0089 in the amount of \$

A Check in the amount of \$725.00 to cover the filing fee(s) is included.

The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-0089.

X Any additional filing fees required under 37 C.F.K. 1.16.

X Any patent application processing fees under 37 C.F.R. 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time fat

submission (37 CFR 1.136)(a)(3).

00000143 10532580

Stephen M. Roylance

Reg. No. 31,296

Bruce H. Bernstein

Reg. No. 29,027

09/16/2005 GFREY1

01 FC:2615

725,00 02

P27726.A04



Applicant

: Jin-Hoi KIM

Group Art Unit: Not Yet Assigned

Appl. No.

: 10/532,580

(U.S. National Stage of PCT/KR2003/002339)

Examiner: Not Yet Assigned

I.A. Filed

: November 4, 2003

For

: PORCINE UROPLAKIN II PROMOTER AND THE PRODUCTION

METHOD OF USEFUL PROTEINS USING SAID PROMOTER

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicant hereby brings the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification and the International Search Report issued in connection with International Patent Application No. PCT/KR2003/002339, of which the present application is the U.S. National Stage Application. A copy of the International Search Report was enclosed with the papers when entering the National Stage on April 25, 2005. The Examiner is invited to review these materials to inspect the relevance indicated during international examination with respect to the documents cited therein. The following is a list of the documents cited in the above-noted documents:

D. N. KWON et al., "Cloning, sequencing, and expression analysis of the porcine uroplakin II gene," Biochemistry and Biophysical Research Communication, Vol. 293, No. 2, pp. 862-869 (2002);

U.S. Patent No. 6,339,183, together with patent family members U.S. Patent Publication No. 2002/0092033 and U.S. Patent No. 6,001,646;

NCBI GeneBank Association No. AY044189, 4 pages including one sequence listing, (2001);

Takahito INOUE et al., "Position-independent human β-globin gene expression mediated by a recombinant adeno-associated virus vector carrying the chicken β-globin insulator," J. Hum Genet, Vol. 44, No. 3, pp. 152-162 (1999); and

Romain ZUFFEREY et al., "Woodchuck Hepatitis Virus

Posttranscriptional Regulatory Element Enhances Expression of Transgenes

Delivered by Retroviral Vectors," Journal of Virology, Vol. 73, No. 4, pp. 2886-2892 (1999).

Further to 37 C.F.R. §1.98 (a)(2)(ii), copies of the U.S. patents are not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

Additionally, Applicant submits a copy of the republished International Patent Application No. PCT/KR03/002339 for purposes of completing the Record.

Except for U.S. Patents, copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is

P27726.A04

accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicant notes that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure consideration of the submitted material. However, if an Office Action on the merits has issued and is crossing this statement in the mail, the Patent and Trademark Office is authorized to charge any fees necessary for entry of this information disclosure statement into the application to Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted, Jin-Hoi KIM

Bruce H. Bernstein

Reg. No. 29,027

Stephen M. Roylance

Reg. No. 31,296

September 7, 2005 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191

if not in conformance and not considered. Include copy of this form with next communication to applicant.